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Human ApoE4 accelerates memory decline in ageing and in Alzheimer’s disease. Although intranasal
insulin can improve cognition, this has little effect in ApoE4 subjects. To understand this ApoE
genotype-dependent effect, we examined brain insulin signaling in huApoE3 and huApoE4 targeted
replacement (TR) mice. At 32 weeks, lower insulin receptor substrate 1 (IRS1) at S636/639 and Akt
phosphorylation at T308 were detected in fasting huApoE4 TR mice as compared to fasting huApoE3 TR
mice. These changes in fasting huApoE4 TR mice were linked to lower brain glucose content and have no
effect on plasma glucose level. However, at 72 weeks of age, these early changes were accompanied by
reduction in IRS2 expression, IRS1 phosphorylation at Y608, Akt phosphorylation at S473, andMAPK (p38
and p44/42) activation in the fasting huApoE4TRmice. The lower brain glucose was significantly associated
with higher brain insulin in the aged huApoE4 TR mice. These results show that ApoE4 reduces brain
insulin signaling and glucose level leading to higher insulin content.
H
uman apolipoprotein E (ApoE) is located on chromosome 19 encoding a 35 kDa protein1 that exists in 3
isoforms, E2, E3 and E42,3. These isoforms differ by amino acid substitutions at two positions (residues 112
and 158)4.
ApoE is synthesized in various organs1 and high expression is detected in the liver5 and in the brain6. In the
peripheral tissues, ApoE is extensively studied as a group of lipid carrier molecules vital to the cholesterol
homeostasis of the body5. But, emerging studies suggest that ApoE has other functions beyond cholesterol
metabolism2,7.
Although ApoE is widely expressed in the brain6, little is known about the role of this protein in brain
function2,8. However, inheriting the ApoE4 isoform is a strong genetic risk factor for Alzheimer’s disease
(AD)9,10. In AD, ApoE4 is linked to poor Ab clearance11–13 and greater Ab deposition14.
Positron emission tomography (PET) using [18F]flurodeoxyglucose (FDG-PET) shows reduced cerebral glu-
cose metabolism in AD subjects15. Older asymptomatic ApoE4 carriers also show reductions in cerebral glucose
metabolism10,16,17 in specific brain regions overlapping with those observed in AD subjects18,19.
While these reports are consistent with ApoE effects on cerebral glucose metabolism in AD, other studies also
showed that the ApoE4 allele is associated with similarmetabolic reductions in young subjects with little or noAb
plaque20,21. To differentiate the contributions of Ab and ApoE genotype to cerebral glucose metabolism, a recent
study using FDG-PET and PET amyloid imaging shows that reduced cerebral glucose metabolism seen in older
ApoE4 carriers is contributed byApoE genotype and not due to aggregatedAb22. These studies indicate that ApoE
gene has other neural functions not related to Ab23–25.
HumanApoE4 is known to acceleratememory decline in ageing andAD10,26–28. Although intranasal insulin can
improve cognition29,30, this has little effect in ApoE4 elderly subjects31. To understand if this neuronal insulin
function is due to ApoE genotype, we have conducted this study to compare the effect of this genetic polymorph-
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Results
Altered brain insulin receptor protein expression and phospho-
rylation in huApoE4 TRmice. Intranasal insulin has been shown to
improve cognition29,30, but this has little effect in ApoE4 non-
demented elderly subjects31. We therefore decided to determine if
ApoE polymorphism can affect neuronal insulin signaling in ageing
huApoE3 and huApoE4 targeted replacement (TR) mice.
As shown in figure 1A, lower phosphorylation of the insulin recep-
tor substrate 1 (IRS1) at serine residue 636/639 (S636/639) was
detected in the fasting huApoE4 TR mice as compared to fasting
huApoE3 TRmice at 32 and 72 weeks of age. Densitometric analysis
indicated a reduction of 59% and 50% IRS1 phosphorylation (S636/
639) at 32 and 72 weeks of age respectively (Figure 1B). In aged (72
weeks) ApoE4TRmice, IRS1 phosphorylation at tyrosine 608 (Y608)
was reduced by 40% as compared to ApoE3 TR mice at similar age
(Figures 1A and 1C).
While total IRS1 expression was not altered between the two
mouse lines (Figure 1A), total IRS2 level was lowered by 45% in 72
weeks old fasting huApoE4 mice (Figure 1A and 1D). However, we
were unable to detect IRS2 phosphorylation at Ser-388 (S388) and
Tyr-978 (Y978).
Lower MAPK activation in the brain of aged huApoE4 TR mice.
Altered IRS1 phosphorylation at S636/639 has been shown to affect
MAPK activation32,33. We therefore examined the expression and
phosphorylation of two major proteins in MAPK signaling; p38
and p44/42. As shown in figure 2, no changes in the expression
and phosphorylation of p38 and p44/42 were detected in 32 weeks
huApoE TR mice.
However, in the 72 weeks old mice, lower phosphorylation of p38
at threonine 180 and tyrosine 182 (T180/Y182), and p44/42 at threo-
nine 202 and tyrosine 204 (T202/Y204) were detected in huApoE4
mice as compared to huApoE3 TRmice at similar age (Figure 2). The
phosphorylation of both protein targets (p38 and p44/42) was
reduced by almost 50% in the brain of aged huApoE4 TR mice.
Reduced Akt phosphorylation in the brain of huApoE4 TR mice.
We next determined if the aberrant IRS expression and phospho-
rylation (Figure 1) will affect the downstreamAkt protein expression
and phosphorylation. Using immunoblotting, we did not detect any
change in total Akt level between the fasting huApoE3 and huApoE4
TRmouse brain (Figure 3A and 3B). However, Akt phosphorylation
at Serine-473 (S473) was reduced by 39% in the brain of 72 weeks old
Figure 1 | Insulin receptor substrate proteins expression in huApoE TRmice. (A)Western blot analysis of insulin receptor substrate-1 and -2 (IRS1 and
IRS2), and phosphorylated IRS1 (S636/639 and Y608) levels in the brain of huApoE3 and huApoE4 TR mice at 32 and 72 weeks of age. b-actin was
immunoblotted to ensure similar gel loading of the starting material in each sample. The blot is a representative of three independent experiments. Blot
images were cropped for comparison. Densitometry analysis of phosphorylated IRS1 at (B) S636/639 and (C) Y608 relative to total IRS1, and (D) total
IRS2 level relative to b-actin level, in 32 and 72weeks old E3 (white bar) and E4 (grey bar)mice was performed using theNIH ImageJ software. Each value
represents themean6 SEM for individualmouse brain sample (n5 3 at each time point for eachmouse line). Lower IRS1 phosphorylation at (S636/639)
was detected in E4 TRmice at 32 and 72 weeks of age as compared to E3 TRmice of similar age. However, lower IRS1 phosphorylation at (Y608) was only
detected in E4 TR mice at 72 weeks of age as compared to E3 TR mice of similar age. Lower total IRS2 level was detected in 72 weeks E4 TR mice as
compared to E3 TR mice at similar age. (*p , 0.05; ** p , 0.04, using Student’s t-test).
www.nature.com/scientificreports
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fasting huApoE4 TRmice as compared to the fasting huApoE3 mice
of similar age (Figure 3A and 3C). In contrast, Akt phosphorylation
at Threonine-308 (T308) was significantly reduced in both 32 and 72
weeks old fasting huApoE4 TR mouse brain as compared to fasting
huApoE3 TR mouse brain at similar age (Figure 3A and 3D). In 32
weeks huApoE4 TR mice, Akt phosphorylation (T308) was reduced
by 61%, whereas the reduction in huApoE4 at 72 weeks was 48%.
Brain insulin and glucose in huApoE TF mice.We then examined
if changes in IRS expression and phosphorylation are linked to
altered brain insulin. As shown in figure 4a, there were no signi-
ficant different in brain insulin level between fasting huApoE3 and
fasting huApoE4 TR mice at 32 weeks of age. At 72 weeks of age,
brain insulin was 20% higher in the fasting huApoE4 TR mice as
compared to the fasting huApoE3 TR mice (Figure 4a line).
Since insulin signaling is associated to cerebral glucose metabol-
ism34,35, it is possible that the mouse brain glucose content could be
affected in ourmouse lines. Unlike the late stage (72weeks) change in
brain insulin, brain glucose was affected as early as 32 weeks of age
(Figure 3a bar). Brain glucose level was significant lower by 26% and
33% in the fasting huApoE4 TR mice as compared to the fasting
huApoE3 TR mice at 32 and 72 weeks of age respectively. This
observation is in line with recent clinical imaging study showing
lower cerebral glucose metabolism in non-demented ApoE4 carriers
as compared to non-demented non-ApoE4 carriers22.
Plasma insulin and glucose in huApoE TF mice. We next deter-
mine if the biochemical change in the mouse brain was related to the
animal blood system. As shown in figure 4b, no change in plasma
glucose and insulin was detected between the fasting huApoE3 TR
and huApoE4 TR mice at both ages.
Brain and plasma cholesterol in huApoE TRmice.ApoE is a major
player in cholesterol metabolism2. We decided to examine if changes
in brain insulin and glucose also affect brain cholesterol. We did not
detect any significant different in brain cholesterol between fasting
huApoE4 and huApoE3 TR mice at 32 and 72 weeks of age
(Figure 5a). Similarly, the plasma cholesterol content was not
significant altered between fasting huApoE3 and huApoE4 mice at
both ages (Figure 5b). This is expected since studies have shown that
plasma cholesterol in these two TR mouse lines are only affected
when they are kept on high-fat diet36–38.
ApoE expression in huApoETRmouse brain.ReducedApoE levels
have been reported in the brain of huApoE4 TR mice39,40 and in
Figure 2 | MAPK expression and phosphorylation in huApoE TRmice. (A) Immunoblotting of total p38 and p44/42, phosphorylated p38 (T180/Y182)
and phosphorylated p44/42 (T202/Y204) in huApoE3 and huApoE4 TRmice at 32 and 72 weeks of age. b-actin was immunoblotted to ensure similar gel
loading of the starting material in each sample. The blot is a representative of three independent experiments. Blot images were cropped for comparison.
Densitometry analysis of (B) phosphorylated p38(T180/Y182) level relative to total p38 and (D) phosphorylated p44/42(T202/Y204) level relative to total
p44/42 level, in 32 and 72 weeks old E3 (white bar) and E4 (grey bar)mice was performed using the NIH ImageJ software. Each value represents themean
6 SEM for individual mouse brain sample (n 5 3 at each time point for each mouse line). Lower p38 phosphorylation (T180/Y182) and p44/42
phosphorylated (T202/Y204) was detected in 72 weeks E4 TR mice as compared to E3 TR mice at similar age. (*p, 0.005; ** p, 0.02, using Student’s
t-test).
www.nature.com/scientificreports
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non-dementedAPOE4 carriers40. However, it is unclear if this altered
ApoE content persists during development.
We therefore immunoblotted for ApoE in the brain of fasting
huApoE3 and huApoE4 TRmice at 32 and 72 weeks of age. As show
in figure 6, lower ApoE content was detected in the brain of young
and old huApoE4 TR mice as compared to huApoE3 TR mice at
similar age.
Discussion
Intranasal insulin can improve cognition29,30, but not in ApoE4 eld-
erly subjects31. In this study, we are reporting an ApoE genotype-
dependent effect on brain insulin signaling. Our results shows that
ApoE4 expression is linked to lower brain insulin signaling and brain
glucose content, and higher brain insulin.
Earlier studies have reported significant cognitive impairment in
female ApoE4mice as compared to male ApoE4mice41–44. We there-
fore decided to examine insulin signaling in the brain of female
ApoE3 and ApoE4 TR mice.
In this study, mice are fasted to trigger a catabolic state when
examining peripheral insulin signaling45. This process will reduce
variability in baseline insulin signaling activation during experiments.
We found that ApoE4 expression reduce the phosphorylation of
IRS1 at S636/639 and at Y608. Altered phosphorylation of this serine
residue (S636/639) on IRS1 has been shown to affect Akt phosphor-
ylation46,47 and deregulate mTOR and MAPK activation32,33. Lower
phosphorylation of p38 and p44/42 were detected in aged ApoE4 TR
mice.
One possible mechanism linking IRS1 and Akt activation is ApoE
expression. Studies have showed that ApoE treatment of primary
neuron increases Akt phosphorylation48. Therefore, the lower brain
ApoE level in huApoE4 TR mice as compared to huApoE3 TR
mice39,40 could reduce Akt phosphorylation. This process may due
to lower IRS1 phosphorylation at Y608 and S636/639.
The effect of ApoE4 on lowering Akt phosphorylation could also
impair synaptic plasticity49 and reduce ApoER2 expression50. Aber-
rant Akt phosphorylation is reported to affect Reelin signaling51
leading to altered ApoER2 expression and synaptic function50. This
synaptic dysfunction may contribute to the reported cognitive
impairment in huApoE4 mice42.
Insulin is an important modulator of growth and metabolic func-
tion52. A reduction in insulin signalling activation can result in dis-
eases such as diabetes and AD52–54. Most of our knowledge on insulin
function is derived from observations in the peripheral organ
Figure 3 | Akt expression and phosphorylation in huApoE TRmice. (A) Immunoblotting of total Akt, phosphoryalted Akt (S473) and phosphorylated
Akt (T308) in huApoE3 and huApoE4 TRmice at 32 and 72weeks of age. b-actin was immunoblotted to ensure similar gel loading of the startingmaterial
in each sample. The blot is a representative of three independent experiments. Blot images were cropped for comparison. Densitometry analysis
of (B) total Akt level relative to b-actin level, (C) phosphorylated Akt(S437) and (D) phosphorylated Akt(T308) level relative to total Akt level, in 32 and
72 weeks old E3 (white bar) and E4 (grey bar) mice was performed using the NIH ImageJ software. Each value represents the mean 6 SEM for individual
mouse brain sample (n5 3 at each time point for eachmouse line). Lower Akt phosphorylation (S473) was detected in 72 weeks E4 TRmice as compared
to E3 TR mice at similar age. However, reduced Akt phosphorylation at T308 can be observed in E4 TR mice at 32 and 72 weeks of age as compared
to E3 TR mice of similar age. (*p , 0.04; ** p , 0.01, using Student’s t-test).
www.nature.com/scientificreports
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systems55. However, recent clinical study has showed functional
separation between brain insulin and peripheral insulin56. Our cur-
rent study also show brain insulin and glucose is distinct from the
blood glucose and insulin in our fasting mice.
However, as the lower brain glucose content was detected in 32
weeks old fasting hApoE4 TRmice, we were uncertain if the changes
in the expression and activation of the brain insulin signaling pro-
teins were the cause or consequence of the brain glucose alteration.
Nevertheless, the late-stage (72 weeks old) elevation of brain insulin
content in the fasting hApoE4 TR mice is likely due to impaired
insulin signaling.
ApoE is extensive studied as a group of lipid carrier molecules that
is vital in the cholesterol homeostasis of the body5, and has been
proposed to have similar function in the brain57. However, in our
fasting hApoE TRmice, changes in the brain insulin and glucose did
not affect the brain cholesterol content. Further, blood cholesterol
remains unchanged alongside blood insulin and glucose in the fast-
ing hApoE TRmice. This is expected since our hApoE TRmice were
not fed with high-fat diet37.
Reduced ApoE levels have been reported in the brain of huApoE4
TR mice39,40 and in non-demented APOE4 carriers40. Here, we have
observed lower ApoE4 level in both young and aged huApoE TR
mice. It is possible that ApoE level is lower inApoE4TRmice at birth.
There is increasing recognition that diabetes is an AD risk fac-
tor58–62. We and others have reported that impaired insulin signaling
could enhance amyloid deposition and pathology54,58–63. PET
imaging has detected lower cerebral glucose metabolism in overlap-
ping brain regions in older asymptomatic ApoE4 carriers10,16,17 and in
AD subjects18,19. It is possible that early changes in insulin signaling
could be detected in these brain regions; including parietal, temporal,
prefrontal and posterior cingulate.
Increasing connection between diabetes and AD has lead to grow-
ing interests to test the effect of anti-diabetic drugs on amyloid
pathology in AD animal models and subjects64–68. Since ApoE can
affect brain insulin signaling, the role of ApoE genotypes on the effect
of anti-diabetic drugs on amyloid pathology in AD animal models
and subjects should be examined.
In summary, our study indicates an interplay between ApoE and
brain insulin signaling. This observation could underlie the ApoE
genotype-dependent effect on cerebral glucose metabolism7,22 and
intranasal insulin action on cognition31. ApoE4 is a strong genetic
risk factor for AD9,10. But it is unclear if the insulin signaling dys-
function detected in AD52,69–71 is ApoE genotype-dependent. Further
studies to examine the impact of ApoE on this pathogenic process
will benefit the understanding and treatment of AD.
Methods
Animals. The experimental protocol (#009/10) involving the maintenance and
euthanasia of laboratorymice was approved by the Institutional Animal Care andUse
Committees (IACUC) at the National University of Singapore. The human
apolipoprotein E3 and E4 targeted replacement mice were created as described37 and
were purchased from Taconic. Briefly, the human APOE genomic fragments were
used to replace the endogenous mouse ApoE gene via homologous recombination.
The mice were kept on 2018 Teklad Global 18% Protein Rodent Diet (Harland
Figure 4 | Analysis of insulin and glucose contents in the brain and
plasma of fasting huApoE TRmice. (A) Lower brain glucose was detected
in E4 TR (grey bar) mice at 32 and 72 weeks of age as compared to E3 TR
mice (white bar) of similar age. But higher brain insulin was only detected
in 72 weeks old E4 TRmice (dotted line) as compared to E3 TRmice (bold
line) at similar age. (B)No significant change in plasma insulin and glucose
contents between E3 TR and E4 TR mice at 32 and 72 weeks of age. Each
value represents the mean 6 SEM of duplicate assays for individual
samples (n 5 5). (*p, 0.04; ** p, 0.001; *** p, 0.004, using Student’s
t-test).
Figure 5 | Analysis of brain and plasma cholesterol contents in fasting
huApoE TR mice. No significant different in (A) brain and (B) plasma
cholesterol contents between E3 TR (white bar) and E4 TR (grey bar) mice
at 32 and 72 weeks of age was detected. Each value represents the mean 6
SEM of duplicate assays for individual samples (n 5 5).
www.nature.com/scientificreports
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Laboratories). Mice were fasted for,12 hours prior to experiments. All experiments
were performed on at least three (n $ 3) fasted female homozygous huApoE3 and
huApoE4 mice at 32 and 72 weeks of age.
Preparation of brain homogenates. Themouse brain tissues were snapped frozen in
liquid nitrogen when harvested and the wet weight of the tissues (in mg) was
determined using an electronic balance. Twenty percent (w/v) brain homogenates
were prepared with 13 cell lysis buffer (Cell Signaling Technology) with protease
inhibitors cocktail (Roche Diagnostic).
The cell lysis buffer contains sodium orthovanadate, pyrophosphate and glycer-
ophosphate, which can acts as phosphatase inhibitors. Lysates were then homoge-
nized using a hand held motorized pestle (Sigma-Aldrich, St. Louis, USA) for 30
seconds on ice. Tissue lysates were subsequently centrifuged at 30,000 g for 30
minutes under 4C. The soluble portion of the lysates was collected for analysis.
Protein quantification of lysates. Tissue lysates were quantified using the PierceTM
MicroBCA assay kit (ThermoFisher Scientific, Waltham, USA) in a 96-well
microplate format. Lysates were diluted in PBS and the working reagent was prepared
and added in accordance to the manufacturer’s instructions. Samples were then
incubated at 37uC for 30 minutes before reading the absorbance values at 562 nm.
Protein concentrations of samples were calculated based on a standard curve
constructed from a range of BSA standards. The brain tissue lysates were aliquoted
and stored at 280uC.
Immunoblot analysis. Fifty micrograms (mg) of soluble brain proteins from lysate
samples were heated at 95uC for 5 minutes. Protein samples were then centrifuged at
14,000 g for 2 minutes on a bench top centrifuge before they were loaded on a 7.5–
10%Tris-glycine polyacrylamide gel. The Precision Plus proteinTM standard (Bio-Rad
Laboratories, Hercules, California USA) was used as amolecular weight standard and
run together with the samples on the same piece of gel.
The separated proteins were transferred onto a nitrocellulose membrane, probed
with the respective antibodies and exposed to horseradish peroxidase (HRP)-con-
jugated secondary antibodies. The reactive protein bands were visualized by
chemiluminescence on the Image Station 4000R (Carestream Health Inc) using the
SuperSignalHWest Dura Substrate (Pierce) system.
Immunoblotting of b-actin using a rabbit polyclonal antibody that binds to the C-
terminal of b-actin (Sigma) was included in all western blot analysis to ensure
comparable protein loading. The primary antibodies used include anti-huApoE
(Santa Cruz Biotechn, Cat# 13521), anti-IRS1 (Cell Signaling Technology, Cat#
2382), anti-pIRS1(S636/639) (Cell Signaling Technology, Cat#2388), anti-pIRS1
(Y608) (Millipore, Cat# 09-432) anti-IRS2 (Cell Signaling Technology, Cat# 4502),
anti-pIRS2 (S388) (Millipore, Cat# 07-1517), anti-pIRS2 (Y978) (Pierce, Cat# PA5-
13025), anti-p38 (Cell Signaling Technology, Cat# 8690), anti-phospho-p38 (T180/
Y182) (Cell Signaling Technology, Cat# 4511), anti-p44/42 (Cell Signaling
Technology, Cat# 4695), anti-phospho-p44/42 (T202/Y204) (Cell Signaling
Technology, Cat# 4370), anti-Akt (Cell Signaling Technology, Cat# 4691), anti-
pAkt(S473) (Cell Signaling Technology, Cat# 4060), and anti-pAkt(T308) (Cell
Signaling Technology, Cat# 2965).
Densitometry analysis was performed63 by measuring the optical densities of the
targeted protein bands relative to the endogenous b-actin level from the same brain
sample. For protein phosphorylation, the optical densities of the phosphorylated
protein bands weremeasured relative to the targeted total protein level from the same
brain sample. The analysis was performed using the NIH ImageJ software.
Glucose assay. Plasma and total brain glucose content was measuring using the
amplex red glucose assay kit (Life Technologies) following the instructions provided
by the manufacturer. Briefly plasma or brain lysate sample was mixed with equal
volume of amplex red working reagent, and the reaction mixture was then incubated
for 30 minutes at room temperature in the dark. The fluorescence values were read at
an excitation wavelength of 545 nm and an emission wavelength of 590 nm. A series
of glucose standards were prepared and run alongside the mouse plasma and brain
samples.
Insulin assay. Plasma and total brain insulin content was measured using the
sandwich ELISA mouse insulin assay system (Millipore) following the instructions
provided by the manufacturer. Briefly, plasma or brain lysates were added to
microtitre plate well pre-coated with anti-insulin antibody. After incubation and
Figure 6 | Lower human apolipoprotein E (huApoE) level in the brain of huApoE4 targeted replacement (TR)mice as compared to huApoE3 TRmice.
(A)Western blot and (B) densitometric analysis of huApoE levels in E3 (white bar) and E4 (grey bar) TRmice at 32 and 72 weeks of age. (A) The blot is a
representative of three independent experiments. Blot images were cropped for comparison. b-actin was immunoblotted to ensure similar gel loading of
the starting material in each sample. (B) Densitometric analysis was performed the NIH ImageJ software. Each value represents the mean 6 SEM for
individual mouse brain sample (n 5 3 at each time point for each mouse line). Brain huApoE level was significant reduced in E4 TRmice as compared to
E3 TR mice of similar age (*p , 0.05 using Student’s t-test).
www.nature.com/scientificreports
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washing, a biotinylated anti-insulin antibody was added. This biotinylated antibody
reacts against a distinctive epitope to that of the coated anti-insulin. The reaction was
incubated for 15 minutes and the absorbance was read at 370 nm. The stop solution
provided by the assay kit was added to the sample when the absorbance was read at
1.8. Immnoreactivity was immediately determined by measuring the absorbance at
450 nm and 590 nm.
Statistical analysis. Significant differences were analyzed using two-tailed Student’s
T-test. A p value of ,0.05 is considered significant.
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